EUVIMEDEUVIMED entdecken
Open Access

Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs

Shafaqat M Rahman iD, David W Buchholz, Brian Imbiakha, Mason C Jager, Justin Leach, Raven M Osborn iD, Ann O Birmingham, Stephen Dewhurst, Hector C Aguilar iD, Anne E Luebke iD

Journal of Virology · 2024

DOI: 10.1128/jvi.00066-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Shafaqat M Rahman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Biomedical Engineering, Neuroscience, Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Interleukin-6, COVID-19, Mice, Inbred C57BL, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19 can cause neurological symptoms such as fever, dizziness, and nausea. However, such neurological symptoms of SARS-CoV-2 infection have been hardly assessed in mouse models. In this study, we infected two commonly used wild-type mouse lines (C57BL/6J and 129/SvEv) and a 129S calcitonin gene-related peptide (αCGRP) null-line with mouse-adapted SARS-CoV-2 and demonstrated neurological signs including fever, dizziness, and nausea. We then evaluated whether a CGRP receptor antagonist, olcegepant, a “gepant” antagonist used in migraine treatment, could mitigate acute neuroinflammatory and neurological signs of SARS-COV-2 infection. First, we determined whether CGRP receptor antagonism provided protection from permanent weight loss in older (>18 m) C57BL/6J and 129/SvEv mice. We also observed acute fever, dizziness, and nausea in all older mice, regardless of treatment. In both wild-type mouse lines, CGRP antagonism reduced acute interleukin 6 (IL-6) levels with virtually no IL-6 release in mice lacking αCGRP. These findings suggest that migraine inhibitors such as those blocking CGRP receptor signaling protect against acute IL-6 release and subsequent inflammatory events after SARS-CoV-2 infection, which may have repercussions for related pandemic or endemic coronavirus outbreaks. IMPORTANCE Coronavirus disease (COVID-19) can cause neurological symptoms such as fever, headache, dizziness, and nausea. However, such neurological symptoms of severe acute respiratory syndrome CoV-2 (SARS-CoV-2) infection have been hardly assessed in mouse models. In this study, we first infected two commonly used wild-type mouse lines (C57BL/6J and 129S) with mouse-adapted SARS-CoV-2 and demonstrated neurological symptoms including fever and nausea. Furthermore, we showed that the migraine treatment drug olcegepant could reduce long-term weight loss and IL-6 release associated with SARS-CoV-2 infection. These findings suggest that a migraine blocker can be protective for at least some acute SARS-CoV-2 infection signs and raise the possibility that it may also impact long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6COVID-19Mice, Inbred C57BLSARS-CoV-2Weight LossDisease Models, AnimalMigraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsAnimalsMiceQuinazolinesCOVID-19 Drug TreatmentCalcitonin Gene-Related PeptideMaleHumansFemalePiperazines

Stichwörter der Autor:innen

COVIDSARS-CoV-2inhibitormigraineviral infectionvirus

Substanzen

Interleukin-6olcegepantCalcitonin Gene-Related Peptide Receptor AntagonistsQuinazolinesCalcitonin Gene-Related Peptideinterleukin-6, mousePiperazines

Autor:innen und Institutionen

  • Departments of Biomedical Engineering, Neuroscience, Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
  • Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
  • Department of Population Medicine, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.

ORCID-Profile: Shafaqat M Rahman, Raven M Osborn, Hector C Aguilar, Anne E Luebke

Förderung

  • NIDCD NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Rahman, S. M., Buchholz, D. W., Imbiakha, B., Jager, M. C., Leach, J., Osborn, R. M., Birmingham, A. O., Dewhurst, S., Aguilar, H. C., & Luebke, A. E. (2024). Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs. Journal of Virology. https://doi.org/10.1128/jvi.00066-24

Vancouver

Rahman SM, Buchholz DW, Imbiakha B, Jager MC, Leach J, Osborn RM, et al. Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs. Journal of Virology. 2024. doi:10.1128/jvi.00066-24

BibTeX
@article{Rahman2024,
  author = {Rahman, Shafaqat M and Buchholz, David W and Imbiakha, Brian and Jager, Mason C and Leach, Justin and Osborn, Raven M and Birmingham, Ann O and Dewhurst, Stephen and Aguilar, Hector C and Luebke, Anne E},
  title = {Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00066-24}
}
Kostenlos starten →